Protac NP18: A New Hope for Prostate Cancer Treatment
/0 Comments/in Preclinical Research, PROTACs/by MaxAI designed cancer drug gets FDA approval for clinical trials
/0 Comments/in Artificial Intelligence, Not PCa related/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/0 Comments/in Observational, Retrospective studies/by MaxNewsletter 2
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the second newsletter from the site. Last week, I had to travel for work, so I might have missed something! Let’s dive right in. We also have a podcast if you prefer to listen to the newsletter, you can […]
Nodularin-R Enhances Abiraterone’s Effectiveness Against Castration-Resistant Prostate Cancer In Vivo
/0 Comments/in Preclinical Research/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/0 Comments/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment cancer vaccine clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide hormone therapy immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy targeted drug delivery theranostics
Latest Posts
- Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients April 16, 2025
- Phase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer April 15, 2025
- Newsletter 15/2025 April 13, 2025
- Phase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT April 11, 2025